Safety, tolerability, and efficacy of a novel topical isotretinoin formulation for the treatment of X-linked or lamellar congenital ichthyosis: Results from a phase 2a proof-of-concept study

Amy S. Paller; John Browning; Lawrence Charles Parish; Christopher G. Bunick; Zachary Rome; Neal Bhatia

doi:10.1016/j.jaad.2022.02.060

Safety, tolerability, and efficacy of a novel topical isotretinoin formulation for the treatment of X-linked or lamellar congenital ichthyosis: Results from a phase 2a proof-of-concept study

Amy S. Paller, John Browning, Lawrence Charles Parish, Christopher G. Bunick^*, Zachary Rome, Neal Bhatia

^*Corresponding author for this work

Dermatology

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Original language	English (US)
Pages (from-to)	1189-1191
Number of pages	3
Journal	Journal of the American Academy of Dermatology
Volume	87
Issue number	5
DOIs	https://doi.org/10.1016/j.jaad.2022.02.060
State	Published - Nov 2022

Funding

Funding sources: Supported by Patagonia Pharmaceuticals and a grant from the US Food and Drug Administration ( 1R01FD006079-01A1 ). Medical writing and editorial assistance were provided by Zehra Gundogan, VMD, of AlphaBioCom, LLC, under the direction of the authors and funded by Timber Pharmaceuticals.

Keywords

congenital ichthyosis
isotretinoin
retinoids
scaling
topical therapy

ASJC Scopus subject areas

Dermatology

Access to Document

10.1016/j.jaad.2022.02.060

Cite this

Paller, A. S., Browning, J., Parish, L. C., Bunick, C. G., Rome, Z., & Bhatia, N. (2022). Safety, tolerability, and efficacy of a novel topical isotretinoin formulation for the treatment of X-linked or lamellar congenital ichthyosis: Results from a phase 2a proof-of-concept study. Journal of the American Academy of Dermatology, 87(5), 1189-1191. https://doi.org/10.1016/j.jaad.2022.02.060

@article{47479813694648489e5f6f893fd9080a,

title = "Safety, tolerability, and efficacy of a novel topical isotretinoin formulation for the treatment of X-linked or lamellar congenital ichthyosis: Results from a phase 2a proof-of-concept study",

keywords = "congenital ichthyosis, isotretinoin, retinoids, scaling, topical therapy",

author = "Paller, {Amy S.} and John Browning and Parish, {Lawrence Charles} and Bunick, {Christopher G.} and Zachary Rome and Neal Bhatia",

note = "Funding Information: Funding sources: Supported by Patagonia Pharmaceuticals and a grant from the US Food and Drug Administration ( 1R01FD006079-01A1 ). Funding Information: Medical writing and editorial assistance were provided by Zehra Gundogan, VMD, of AlphaBioCom, LLC, under the direction of the authors and funded by Timber Pharmaceuticals.",

year = "2022",

month = nov,

doi = "10.1016/j.jaad.2022.02.060",

language = "English (US)",

volume = "87",

pages = "1189--1191",

journal = "Journal of the American Academy of Dermatology",

issn = "0190-9622",

publisher = "Elsevier Inc.",

number = "5",

}

Paller, AS, Browning, J, Parish, LC, Bunick, CG, Rome, Z & Bhatia, N 2022, 'Safety, tolerability, and efficacy of a novel topical isotretinoin formulation for the treatment of X-linked or lamellar congenital ichthyosis: Results from a phase 2a proof-of-concept study', Journal of the American Academy of Dermatology, vol. 87, no. 5, pp. 1189-1191. https://doi.org/10.1016/j.jaad.2022.02.060

Safety, tolerability, and efficacy of a novel topical isotretinoin formulation for the treatment of X-linked or lamellar congenital ichthyosis: Results from a phase 2a proof-of-concept study. / Paller, Amy S.; Browning, John; Parish, Lawrence Charles et al.
In: Journal of the American Academy of Dermatology, Vol. 87, No. 5, 11.2022, p. 1189-1191.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Safety, tolerability, and efficacy of a novel topical isotretinoin formulation for the treatment of X-linked or lamellar congenital ichthyosis

T2 - Results from a phase 2a proof-of-concept study

AU - Paller, Amy S.

AU - Browning, John

AU - Parish, Lawrence Charles

AU - Bunick, Christopher G.

AU - Rome, Zachary

AU - Bhatia, Neal

N1 - Funding Information: Funding sources: Supported by Patagonia Pharmaceuticals and a grant from the US Food and Drug Administration ( 1R01FD006079-01A1 ). Funding Information: Medical writing and editorial assistance were provided by Zehra Gundogan, VMD, of AlphaBioCom, LLC, under the direction of the authors and funded by Timber Pharmaceuticals.

PY - 2022/11

Y1 - 2022/11

KW - congenital ichthyosis

KW - isotretinoin

KW - retinoids

KW - scaling

KW - topical therapy

UR - http://www.scopus.com/inward/record.url?scp=85127320828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85127320828&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2022.02.060

DO - 10.1016/j.jaad.2022.02.060

M3 - Article

C2 - 35271936

AN - SCOPUS:85127320828

SN - 0190-9622

VL - 87

SP - 1189

EP - 1191

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

IS - 5

ER -

Safety, tolerability, and efficacy of a novel topical isotretinoin formulation for the treatment of X-linked or lamellar congenital ichthyosis: Results from a phase 2a proof-of-concept study

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this